Life Saving Treatments Celebrated at BayBio’s 11th Annual Pantheon Awards
SOUTH SAN FRANCISCO, CA – Dec 2, 2014 – Nearly one in five new FDA approvals and more than one in four IPOs in 2014 came from Bay Area companies. BayBio will celebrate this record of success at its 11th annual BayBio Pantheon DiNA Awards ceremony on December 11, 2014.
BayBio will recognize two individuals for their contributions to bringing life-saving and
-enhancing drugs and medical devices to patients. Alan Mendelson, a pioneering lawyer whose counsel helped launch dozens of emerging life science companies, is a partner in the Silicon Valley office of Latham & Watkins LLP and a global Co-chair of the firm’s Life Sciences Industry Group. Dr. Lou Lange, the M.D. turned CEO of CV Therapeutics whose preeminent work in molecular cardiology ultimately changed the FDA approval landscape, is now a general partner at Assett Management Ventures.
Other 2014 BayBio DiNA Award recipients include (listed alphabetically by award title):
- Biotechnology Educator: Bay Area Biotechnology Education Consortium (BABEC)
- Digital Health Innovation: Google[x] Life Sciences
- Outstanding Company: Pharmacyclics, Inc.
- Outstanding Partnering: CytomX, Inc.
- Outstanding Product (Device or Diagnostic): M6¬Æ Artificial Disc by Spinal Kinetics
- Outstanding Product (Therapeutic): SOVALDI¬Æ (Sofosbuvir) by Gilead Sciences, Inc.
- Outstanding Public Support: The Honorable Bill Quirk, PhD, Member, California State Assembly
- Rising Star: Caleb Bell, PhD, Founder and CEO, Bell Biosystems
“2014 has been a tremendous year for the life sciences in Northern California and nationally,” said BayBio President and CEO Gail Maderis. “We applaud the people and companies who have dedicated their work to improving patients’ health.”
Communications Director, BayBio